Blackstone’s Acquisition AYUMI Pharmaceutical


Simpson Thacher is representing Blackstone in connection with its acquisition of the entire equity stake in AYUMI Pharmaceutical.

The acquisition will mark Blackstone’s first control private equity investment in Japan. The transaction is expected to close in the second quarter of 2019 and is subject to regulatory approvals and customary closing conditions.

AYUMI Pharmaceutical is a leading specialty pharmaceutical company in Japan focused on Anti-Rheumatism and Orthopedics.

The Simpson Thacher team for the transaction includes David Sneider (Picture), Ian Ho and Yui Hirohashi (M&A); Shahpur Kabraji and Atsushi Usui (Credit); Etienne Renaudeau and Megan Griffith (Antitrust); Steven Klar (Funds); and Jon Goldstein (Tax).

Involved fees earner: Jonathan Goldstein – Simpson Thacher & Bartlett; Megan Griffith – Simpson Thacher & Bartlett; Yui Hirohashi – Simpson Thacher & Bartlett; Ian Ho – Simpson Thacher & Bartlett; Shahpur Kabraji – Simpson Thacher & Bartlett; Steven Klar – Simpson Thacher & Bartlett; Étienne Renaudeau – Simpson Thacher & Bartlett; David Sneider – Simpson Thacher & Bartlett; Atsushi Usui – Simpson Thacher & Bartlett;

Law Firms: Simpson Thacher & Bartlett;

Clients: Blackstone;

Print Friendly, PDF & Email
Avatar

Author: Michael Patrini